Statin Adherence & Risk for New-Onset Type 2 Diabetes | NDEI

Click here for the Slide Library.
Click here to return to

  • This slide shows new-onset type 2 diabetes incidence and characteristics associated with low or very low statin adherence in a cohort study investigating the relationship between increasing levels of statin adherence and new-onset type 2 diabetes.
  • A total of 11,154 of 115,709 subjects received antihyperglycemic therapy or were hospitalized for type 2 diabetes (study outcomes). The incidence rate was 14.9 new cases of diabetes/1,000 person-years.
  • >50% of subjects had very low or low statin adherence (57% vs 43% with intermediate or high adherence).
  • Very low or low statin adherence was more common in:
    • Women
    • Initial therapy with fluvastatin or pravastatin
    • No use of other medications
    • No previous CVD hospitalization
    • No chronic comorbidities

This cohort study investigated the relationship between increasing levels of statin adherence and type 2 diabetes. Subjects were from the database of National Health Service in Italy and had ≥1 new statin prescription and no prior diabetes (N=115,709). Adherence was assessed by proportion of days covered (PDC): the cumulative number of days medication was available divided by days of follow-up. Adherence was categorized as very low (PDC <25%), low (PDC 25-49%), intermediate (PDC 50-74%), and high (PDC ≥75%). PDC categories were also considered based on statin potency: rosuvastatin ≥10 mg, atorvastatin ≥20 mg, and simvastatin ≥40 mg considered higher potency; all other statins classified as lower potency. The study outcomes were initiation of antihyperglycemic therapy or hospitalization for type 2 diabetes.

CVD=cardiovascular disease

Corrao G, Ibrahim B, Nicotra F, et al. Statins and the risk of diabetes: evidence from a large population-based cohort study. Diabetes Care. 2014;37(8):2225-2232.

Any pharmacologic agents discussed are approved for use in the United States by the U.S. Food and Drug Administration (FDA) unless otherwise noted. Consult individual prescribing information for approved uses outside of the United States.

August 2014

This slide was created by KnowledgePoint360 Group, LLC, and was not associated with funding via an educational grant or a promotional/commercial interest.